Global Cancer Vaccines Market Overview:
According to SPER Market Research, the Global Cancer Vaccines Market is estimated to reach USD 20.09 billion by 2032 with a CAGR of 12.82%.
Vaccines are medications that boost the body's immune system to defend it from foreign substances. Cancer vaccines are medicines that act as biological response modifiers. Foreign bodies are destroyed by an activated immune system. Vaccines function on the theory of memorizing foreign particles and preventing illness caused by these foreign particles when they invade again. Cancer vaccines are classified as biological response modifiers. These modifiers function by activating the immune system to combat illness. Broadly, cancer vaccines are of two types: prevention vaccines and treatment vaccines. In order to prevent cancer, healthy people are given preventive cancer vaccinations. Patients with cancer are given therapeutic cancer vaccines to boost their immune system's ability to combat the disease. Cancer vaccinations can be given intravenously (IV) to both adults and children.
Impact of COVID-19 on the Global Cancer Vaccines Market
The market for Global Cancer Vaccines Market production and distribution firms have been impacted to a limited amount by COVID-19, owing to shutdowns in various COVID-19 afflicted nations and an increase in the number of healthcare professionals becoming ill in the of the pandemic, resulting in low supply. The pandemic has hampered cancer vaccine manufacturing as well as the import and export of raw materials and completed goods owing to shutdowns in various COVID-19-affected nations. Due to rising product approvals in emerging nations and major industry players' increased focus on clinical research for the development of innovative vaccines, the pandemic also drove the market. The pandemic reduced the population's rate of cancer vaccination, but growing consumer awareness and a high demand for cancer vaccines are two instances of the market's slow growth.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2032 |
| Base year considered | 2021 |
| Forecast period | 2022-2032 |
| Segments covered | By Technology, By Type, By Indication, By End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Companies Covered | Aduro Biotech, Advantagene, Advaxis, Agenus, Altor BioScience, Argos Therapeutics, Dendreon, GlaxoSmithKline, Onco Thyreon, Oncovir, Oxford BioMedical, Prsima BioMed, Sotio, Transgene, Ubivac, Vaccinogen, Vaxon Biotech. |
Global Cancer Vaccines Market Segmentation:
By Technology: Based on the Technology, Global Cancer Vaccines Market is segmented as; Dendritic Cells (DC) Cancer Vaccines, Recombinant Cancer Vaccines, Antigen/Adjuvant Cancer Vaccines, Viral Vector & DNA Cancer Vaccines.
By Type: Based on the Type, Global Cancer Vaccines Market is segmented as; Preventive Cancer Vaccines, Therapeutic Cancer Vaccines.
By Indication: Based on the Indication, Global Cancer Vaccines Market is segmented as; Cervical Cancer, Prostate Cancer Others.
By End User: Based on the End User, Global Cancer Vaccines Market is segmented as; Pediatrics, Adults.
By Region: Due to rising cancer fatalities, North America is expected to account for the highest proportion of the global cancer vaccines market. Due to growing government initiatives, businesses focusing more on the India vaccine technology market, and growing immunisation programmes by the World Health Organization and GAVI, Asia Pacific is anticipated to have the most growth.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Cancer Vaccines Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4.Heat map analysis
6. Global Cancer Vaccines Market, By Technology, 2019-2032 (USD Million)
6.1. Antigen/Adjuvant Cancer Vaccines
6.2. Dendritic Cells (DC) Cancer Vaccines
6.3. Recombinant Cancer Vaccines
6.4. Viral Vector & DNA Cancer Vaccines
7. Global Cancer Vaccines Market, By Type, 2019-2032 (USD Million)
7.1. Preventive Cancer Vaccines
7.2. Therapeutic Cancer Vaccines
8. Global Cancer Vaccines Market, By Indication, 2019-2032 (USD Million)
8.1. Cervical Cancer
8.2. Prostate Cancer
8.3. Others.
9. Global Cancer Vaccines Market, By End User, 2019-2032 (USD Million)
9.1. Pediatrics
9.2. Adults
10. Global Cancer Vaccines Market, By Region, 2019-2032 (USD Million)
10.1. North America
10.1.1. Canada
10.1.2. Mexico
10.1.3. United States
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Rest of Europe
10.2.5. Spain
10.2.6. United Kingdom
10.3. Asia-Pacific
10.3.1. Australia
10.3.2. China
10.3.3. India
10.3.4. Japan
10.3.5. Rest of Asia-Pacific
10.3.6. South Korea
10.4. South America
10.4.1. Brazil
10.4.2. Argentina
10.4.3. Rest of South America
10.5. Middle East & Africa
10.5.1. Kingdom of Saudi Arabia
10.5.2. United Arab Emirates
10.5.3. Rest of Middle East & Africa
11. Company Profiles
11.1. Aduro Biotech
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Advantagene
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. Advaxis
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Agenus
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Altor BioScience
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Argos Therapeutics
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. Dendreon
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. GlaxoSmithKline
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. OncoThyreon
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Oncovir
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Oxford BioMedical
11.11.1. Company details
11.11.2. Financial outlook
11.11.3. Product summary
11.11.4. Recent developments
11.12. Prsima BioMed
11.12.1. Company details
11.12.2. Financial outlook
11.12.3. Product summary
11.12.4. Recent developments
11.13. Sotio
11.13.1. Company details
11.13.2. Financial outlook
11.13.3. Product summary
11.13.4. Recent developments
11.14. Transgene
11.14.1. Company details
11.14.2. Financial outlook
11.14.3. Product summary
11.14.4. Recent developments
11.15. Ubivac
11.15.1. Company details
11.15.2. Financial outlook
11.15.3. Product summary
11.15.4. Recent developments
11.16. Vaccinogen
11.16.1. Company details
11.16.2. Financial outlook
11.16.3. Product summary
11.16.4. Recent developments
11.17. Vaxon Biotech
11.17.1. Company details
11.17.2. Financial outlook
11.17.3. Product summary
11.17.4. Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
